Lepu Biopharma Co (HKSE:02157) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02157 Lepu Biopharma Co Ltd HKSE:02157
44 GF Score
Price HK$4.65
GF Value HK$15.69
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Lepu Biopharma Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HKSE:02157
44GF Score
Lepu Biopharma Co Ltd HKSE:02157
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?

Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued. The current stock price of HK$4.65 is trading 70.4% below its estimated GF Value™ of HK$15.69. GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.

Key valuation signals for HKSE:02157:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: HK$15.69 vs. price of HK$4.65 (70.4% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lepu Biopharma Co Business Description

Address Lianheng Road, Block 4, No. 651, Minhang District, Shanghai, CHN, 201112
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for HKSE:02157

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.65
Price
HK$15.69
GF Value